These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 16984214)

  • 1. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
    Björkman S
    Br J Clin Pharmacol; 2005 Jun; 59(6):691-704. PubMed ID: 15948934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.
    Vogt W
    Clin Pharmacokinet; 2014 Jan; 53(1):51-72. PubMed ID: 23839530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
    Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
    AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
    Edginton AN; Willmann S
    Clin Pharmacokinet; 2008; 47(11):743-52. PubMed ID: 18840029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
    Rasool MF; Khalil F; Läer S
    Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.
    Ye M; Nagar S; Korzekwa K
    Biopharm Drug Dispos; 2016 Apr; 37(3):123-41. PubMed ID: 26531057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data.
    Claassen K; Thelen K; Coboeken K; Gaub T; Lippert J; Allegaert K; Willmann S
    Curr Pharm Des; 2015; 21(39):5688-98. PubMed ID: 26323410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights.
    Machado TR; Honorio T; Souza Domingos TF; Candido de Paula DDS; Cabral LM; Rodrigues CR; Abrahim-Vieira BA; Teles de Souza AM
    Br J Clin Pharmacol; 2023 Oct; 89(10):3175-3194. PubMed ID: 37293836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanistic approach for the scaling of clearance in children.
    Edginton AN; Schmitt W; Voith B; Willmann S
    Clin Pharmacokinet; 2006; 45(7):683-704. PubMed ID: 16802850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children.
    Price K; Haddad S; Krishnan K
    J Toxicol Environ Health A; 2003 Mar; 66(5):417-33. PubMed ID: 12712630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation of differential drug pharmacokinetics under heat and exercise stress using a physiologically based pharmacokinetic modeling approach.
    Sidhu P; Peng HT; Cheung B; Edginton A
    Can J Physiol Pharmacol; 2011 May; 89(5):365-82. PubMed ID: 21627485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Björkman S
    Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.